Literature DB >> 23606010

Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study.

Yu-Hung Lin1, Mei-Zen Huang, Jiann-Loung Hwang, Heng-Ju Chen, Bih-Chwen Hsieh, Lee-Wen Huang, Chii-Ruey Tzeng, Kok-Min Seow.   

Abstract

PURPOSE: Embryo cryopreservation after triggering oocyte maturation with GnRH agonist (GnRHa) in GnRH antagonist protocols has been proposed to prevent ovarian hyperstimulation syndrome (OHSS). However, a small percentage of patients still developed severe OHSS. The purpose of the study was to investigate the efficacy of preventing OHSS in patients at very high risk when cabergoline was given in addition to elective cryopreservation after GnRHa triggering.
METHODS: This is a retrospective observational study. The patients were stimulated with GnRH antagonist protocol. When serum E2 concentration was >6,000 pg/ml and there were more than 20 follicles ≥11 mm on the day of final oocyte maturation, GnRHa was used to trigger oocyte maturation. Cabergoline was given to augment the effect of preventing OHSS. The embryos were electively cryopreserved by vitrification and thawed in subsequent cycles. The primary outcome measure was the incidence of severe OHSS. The secondary outcome measure was the clinical pregnancy rate in the first frozen-thawed embryo transfer cycle.
RESULTS: One hundred and ten patients underwent 110 stimulated cycles were included for analysis. No patients developed moderate/severe OHSS. Mean E2 concentration on the day of final oocyte maturation was 7,873 pg/ml, and an average of 22.7 oocytes was obtained from each patient. One hundred and ten thawing cycles were performed, resulting in 69 clinical pregnancies (62.7 %).
CONCLUSIONS: Combining cabergoline and embryo cryopreservation after GnRHa triggering in GnRH antagonist protocol could prevent OHSS in patients at very high risk.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23606010      PMCID: PMC3696444          DOI: 10.1007/s10815-013-9997-x

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  51 in total

1.  A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.

Authors:  E M Kolibianakis; A Schultze-Mosgau; A Schroer; A van Steirteghem; P Devroey; K Diedrich; G Griesinger
Journal:  Hum Reprod       Date:  2005-06-24       Impact factor: 6.918

2.  Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study.

Authors:  P Humaidan; L Bungum; M Bungum; C Yding Andersen
Journal:  Reprod Biomed Online       Date:  2006-08       Impact factor: 3.828

3.  Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.

Authors:  Evangelos G Papanikolaou; Cristina Pozzobon; Efstratios M Kolibianakis; Michel Camus; Herman Tournaye; Human M Fatemi; Andre Van Steirteghem; Paul Devroey
Journal:  Fertil Steril       Date:  2006-01       Impact factor: 7.329

Review 4.  Ovarian hyperstimulation: effects of GnRH analogues. Ovarian hyperstimulation syndrome after using gonadotrophin-releasing hormone analogue as a trigger of ovulation: causes and implications.

Authors:  S Kol; N Lewit; J Itskovitz-Eldor
Journal:  Hum Reprod       Date:  1996-06       Impact factor: 6.918

5.  GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.

Authors:  G Griesinger; K Diedrich; P Devroey; E M Kolibianakis
Journal:  Hum Reprod Update       Date:  2005-10-27       Impact factor: 15.610

6.  Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome.

Authors:  Ragaa Mansour; Mohamed Aboulghar; Gamal Serour; Yehia Amin; Ahmed M Abou-Setta
Journal:  Hum Reprod       Date:  2005-07-08       Impact factor: 6.918

7.  GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.

Authors:  P Humaidan; H Ejdrup Bredkjaer; L Bungum; M Bungum; M L Grøndahl; L Westergaard; C Yding Andersen
Journal:  Hum Reprod       Date:  2005-03-10       Impact factor: 6.918

8.  Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.

Authors:  Raul Gomez; Miguel Gonzalez-Izquierdo; Ralf C Zimmermann; Edurne Novella-Maestre; Isabel Alonso-Muriel; Jose Sanchez-Criado; Jose Remohi; Carlos Simon; Antonio Pellicer
Journal:  Endocrinology       Date:  2006-08-10       Impact factor: 4.736

9.  Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.

Authors:  G Griesinger; S von Otte; A Schroer; A K Ludwig; K Diedrich; S Al-Hasani; A Schultze-Mosgau
Journal:  Hum Reprod       Date:  2007-02-15       Impact factor: 6.918

10.  Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups.

Authors:  R H Asch; H P Li; J P Balmaceda; L N Weckstein; S C Stone
Journal:  Hum Reprod       Date:  1991-11       Impact factor: 6.918

View more
  2 in total

1.  Progestin primed ovarian stimulation using corifollitropin alfa in PCOS women effectively prevents LH surge and reduces injection burden compared to GnRH antagonist protocol.

Authors:  Ting-Chi Huang; Mei-Zen Huang; Kok-Min Seow; Ih-Jane Yang; Song-Po Pan; Mei-Jou Chen; Jiann-Loung Hwang; Shee-Uan Chen
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

2.  Severe ovarian hyperstimulation syndrome: Can we eliminate it through a multipronged approach?

Authors:  Nikita Naredi; S K Singh; Prasad Lele; N Nagraj
Journal:  Med J Armed Forces India       Date:  2017-06-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.